PHO-COG-FALLON-ACNS0332; Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotrectinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: medulloblastoma | pineoblastoma
Age: Between 3 - 21 Years
Gender: Male or Female
Histologically confirmed diagnosis of medulloblastoma
Meets 1 of the following criteria: M0 medulloblastoma with > 1.5 cm^2 residual tumor, M+ medulloblastoma, M0 or M+ supratentorial PNET (including pineoblastoma), Diffusely anaplastic medulloblastoma with any M-stage or residual tumor
Must have undergone stereotactic biopsy or attempted neurosurgical resection of the tumor within the past 31 days
Karnofsky performance status (PS) 30-100% (for patients > 16 years of age) OR Lansky PS 30-100% (for patients ? 16 years of age)
Life expectancy > 8 weeks
pregnant or nursing
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required